Optimal Chemo-Hormonal Sequencing for metastatic castrate resistant prostate cancer (mCRPC) maybe Taxotere – Zytiga – Jevtana – Xtandi
The FDA has Agreed to Grant A Priority Review of Xtandi for Men Who are Castrate Sensitive
ADT With and Without Xtandi in Men with Metastatic Hormone Sensitive Prostate Cancer: The ARCHES Trial
The ENZAMET Study: Adding Enzalutamide to ADT in Metastatic Hormone-Sensitive Prostate Cancer Extends Survival
An Expanded Use of Xtandi in Canada
The Synergy between Xtandi and Zytiga with ADT – Is it Important to Continue Taking ADT Along with Xtandi and Zytiga?
Xofigo (Radium-223) - Cautionary Information
The European Medicines Agency (EMA) has recommended that the use of Xofigo (Radium-223) be restricted. The restrictions, because of safety and efficacy concerns in men with castrate resistant prostate cancer (mCRPC), include that Xofigo can be used only after two other treatments have been taken; when other therapies cannot be used and not in combination with other 2nd line hormone therapies.
AR-V7 Liquid Biopsy Coming of Age
Once a man is castrate resistant and moves on a second line hormone therapy drug like Zytiga or Xtandi (aka AR inhibitors) it is inevitable that the Zytiga or Xtandi will also become ineffective.
When this happens, the question that comes is what should be the next treatment? Generally, the options currently available are either to move to the drug not initially used ( Zytiga if Xtandi was first used or Xtandi if Zytiga was used) or instead to use taxane chemotherapy (Taxotere aka docetaxel).
Statin Use Along with Zytiga or Xtandi Extends Survival in Men Who Failed Chemotherapy
Statins have been in the prostate cancer news feeds for a long time. They are believed to potentiate the effects of the anti-hormonal agents used to treat metastatic castration-resistant prostate cancer (mCRPC). Different stages of prostate cancer as well as different treatment exposures might change the efficacy of statins.
